FDAnews
www.fdanews.com/articles/149802-novabay-pharmaceuticals-receives-2-6-million-from-partner-galderma

NovaBay Pharmaceuticals Receives $2.6 Million From Partner Galderma

September 28, 2012
NovaBay Pharmaceuticals, a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides, today announced that it has received $2.6 million from partner Galderma S.A., a global leading pharmaceutical company exclusively focused on dermatology.
Equities